Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02401048 · ClinicalTrials.gov registry record · Phase 1
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02401048 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 61 participants.
The verdict
NCT02401048, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Interventions
- DRUG Ibrutinib
- DRUG MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02401048
The ClinicalTrials.gov registry entry for NCT02401048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT02401048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02401048 about?
NCT02401048 is a clinical study titled "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas". The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
What is the current status of trial NCT02401048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2015-05. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02401048?
The interventions under investigation include: Ibrutinib (DRUG), MEDI4736 (DRUG).
Who is sponsoring clinical trial NCT02401048?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.